Guaifenesin And Pseudoephedrine Hcl Tablet, Extended Release
NDC Package 55111-798-41
Package Information
Guaifenesin And Pseudoephedrine Hcl tablets is ■ do not crush, chew, or break tablet■ take with a full glass of water■ this product can be administered without regard for timing of meals■ children under 12 years of age: do not useFor 600 mg/60 mg■ adults and children 12 years and older: 2 tablets every 12 hours; not more than 4 tablets in 24 hours For 1200 mg/120 mg■ adults and children 12 years and older: 1 tablet every 12 hours; not more than 2 tablets in 24 hours. This formulation utilizes a tablet, extended release delivery system. Marketed by Dr. Reddys Laboratories Limited, this product is identified by NDC 55111-798 and is authorized under FDA application ANDA208369.
Identification & Billing
- RxCUI: 1244675 - guaiFENesin 1200 MG / pseudoephedrine HCl 120 MG 12HR Extended Release Oral Tablet
- RxCUI: 1244675 - 12 HR guaifenesin 1200 MG / pseudoephedrine hydrochloride 120 MG Extended Release Oral Tablet
- RxCUI: 1305603 - guaiFENesin 600 MG / pseudoephedrine HCl 60 MG 12HR Extended Release Oral Tablet
- RxCUI: 1305603 - 12 HR guaifenesin 600 MG / pseudoephedrine hydrochloride 60 MG Extended Release Oral Tablet
- RxCUI: 1305603 - guaifenesin 600 MG / pseudoephedrine hydrochloride 60 MG 12 HR Extended Release Oral Tablet
Clinical Specifications
- Adrenergic alpha-Agonists - [MoA] (Mechanism of Action)
- Decreased Respiratory Secretion Viscosity - [PE] (Physiologic Effect)
- Expectorant - [EPC] (Established Pharmacologic Class)
- Increased Respiratory Secretions - [PE] (Physiologic Effect)
- alpha-Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 55111 - Dr. Reddys Laboratories Limited
- 55111-798 - Guaifenesin And Pseudoephedrine Hcl
- 55111-798-41 - 2 BLISTER PACK in 1 CARTON / 18 TABLET, EXTENDED RELEASE in 1 BLISTER PACK
- 55111-798 - Guaifenesin And Pseudoephedrine Hcl
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (55111-798). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 55111-798-41 identifies a specific commercial package of 2 blister pack in 1 carton / 18 tablet, extended release in 1 blister pack of Guaifenesin And Pseudoephedrine Hcl, a human over the counter drug labeled by Dr. Reddys Laboratories Limited. This tablet, extended release is formulated for oral use and contains guaifenesin; pseudoephedrine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Dr. Reddys Laboratories Limited on December 29, 2017. The current certification is valid through December 31, 2026.
How is this Dr. Reddys Laboratories Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 55111079841. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 2 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.